NCT06495814View on ClinicalTrials.gov

Characterization and Mechanism Research of the Pre-disease State of Obese Type 2 Diabetes Mellitus

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

380

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2026

Conditions

Obese Impaired Glucose ToleranceNewly Diagnosed Obese Type 2 Diabetic Patients

Interventions

DRUG

1/bag of Jinlida granules, 3 times/day, taken with hot water.

All observation and intervention groups received lifestyle interventions, with only the intervention group of high-risk obese impaired glucose tolerance receiving intervention with Jinlida granules.

All Listed Sponsors

lead

Fengmei Lian

OTHER